Multi-Center Project: BETTER CARE - HF (Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure)

NYU Langone Health4 sites in 1 country3,999 target enrollmentApril 4, 2025

ConditionsHeart Failure

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Heart Failure
Sponsor: NYU Langone Health
Enrollment: 3999
Locations: 4
Primary Endpoint: Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA)
Status: Active, not recruiting
Last Updated: last month

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study will test an automated, electronic health record (EHR-)embedded alert to improve prescribing of guideline-directed medical therapy for patients with heart failure and reduced ejection fraction (HFrEF). The investigators have previously tested and implemented this alert at NYU Langone Health (NYULH), and will now test and implement this alert across three other health systems.

Registry

clinicaltrials.gov

Start Date

April 4, 2025

End Date

March 29, 2026

Last Updated

last month

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

NYU Langone Health

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient with an encounter visit at participating cardiology practice during the study period
•Patient with EF of less than or equal to 40% on most recent echocardiogram at the time of visit
•Patient ages 18-90

Exclusion Criteria

•Pregnancy
•Ventricular assist device
•Cardiac amyloid
•Medication-specific exclusion for MRA: most recent systolic blood pressure less than 105 mm Hg, most recent potassium \< 5.1, any potassium \> 5.5, most recent glomerular filtration rate \< 30 (using MDRD equation), or a documented MRA allergy.

Outcomes

Primary Outcomes

Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA)

Time Frame: Up to Day 30

Measured at the prescription encounter level using patient EHR data.

Secondary Outcomes

Number of Patients who are Hospitalized(Up to Month 36)
Number of Patients who are Hospitalized for Heart Failure (HF)(Up to Month 36)
Number of Patients with a Prescription for Beta-Blocker (BB)(Up to Day 30)
Number of Patients with a Prescription for ACE-I/ARB/ARNI(Up to Month 36)
Number of Patients with a Prescription for Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i)(Up to Month 36)
Number of Patients with Hyperkalemia(Up to Month 36)